Methotrexate and Hemodialysis
Authors: KENNETH R. HANDE
Journal: Annals of Internal Medicine (1977)

Letters and Corrections1 October 1977Methotrexate and HemodialysisKENNETH R. HANDE, M.D., JAMES E. BALOW, M.D., JAMES C. DRAKE, B.A., STEVEN A. ROSENBERG, M.D., PH.D., BRUCE A. CHABNER, M.D., F.A.C.P.KENNETH R. HANDE, M.D.Search for more papers by this author, JAMES E. BALOW, M.D.Search for more papers by this author, JAMES C. DRAKE, B.A.Search for more papers by this author, STEVEN A. ROSENBERG, M.D., PH.D.Search for more papers by this author, BRUCE A. CHABNER, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-87-4-495_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Recent successful results using "high-dose" methotrexate with citrovorum factor rescue in the treatment of head and neck carcinoma and osteogenic sarcoma have led to more widespread use of this therapy in the treatment of these and other tumors. A major complication of high-dose methotrexate therapy has been impairment of renal function with rising serum creatinine levels and lowered creatinine clearance. This toxicity has led to delayed renal excretion of methotrexate, which subsequently produces myelosuppression in spite of standard citrovorum factor rescue (1). Removal of methotrexate from patients with impaired renal function would be beneficial in decreasing the...References1. STOLLER R, HANDE K, JACOBS S, ROSENBERG S, and CHABNER B: Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med, in press Google Scholar2. BENNETT W, SINGER I, GOLPER T, FEIG P, and COGGINS C: Guidelines for drug therapy in renal failure. Ann Intern Med 86:754-783, 1977 LinkGoogle Scholar3. MYERS C, LIPPMAN M, ELIOT H, and CHABNER B: Competitive protein binding assay for methotrexate. Proc Natl Acad Sci USA 72:3683-3686, 1975 CrossrefMedlineGoogle Scholar4. LIEGLER D, HENDERSON E, HAHN M, and OLIVERIO V: The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 10:849-857, 1969 CrossrefMedlineGoogle Scholar5. CHABNER B, JOHNS D, and BERTINO J: Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Nature 239:395-397, 1972 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: KENNETH R. HANDE, M.D.; JAMES E. BALOW, M.D.; JAMES C. DRAKE, B.A.; STEVEN A. ROSENBERG, M.D., PH.D.; BRUCE A. CHABNER, M.D., F.A.C.P.Affiliations: Division of Cancer Treatment National Cancer Institute National Institutes of Health Bethesda, MD 20014 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byExtracorporeal Treatment for Methotrexate PoisoningToxicité rénale du méthotrexate à haute doseDrug Removal Systems and Induction ChemotherapyWirkstoffeliminationssysteme und InduktionschemotherapieMethotrexate for rheumatoid arthritis patients who are on hemodialysisDrug Removal Systems and Induction ChemotherapyMethotrexate intoxicity treated with hemodialysis and charcoal hemoperfusion in 12-year-old boyFatal Pancytopenia in a Hemodialysis Patient After Treatment With Low-Dose MethotrexateMethotrexate Clearance by High-Flux Hemodialysis and Peritoneal Dialysis: A Case ReportEFFECT OF CHARCOAL HEMOPERFUSION FOR REMOVAL OF PLASMA METHOTREXATE IN A PATIENT WITH ACUTE RENAL FAILURELes critères d’utilisation de la carboxypeptidase dans les surexpositions au méthotrexate doivent être mieux définisUnderstanding and Managing Methotrexate NephrotoxicityDosing of Antirheumatic Drugs in Renal Disease and DialysisHigh-dose methotrexate-induced nephrotoxicity in patients with osteosarcomaToward a better understanding of methotrexateUse of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiencyHigh-Dose Leucovorin as Sole Therapy for Methotrexate ToxicityCrystal-induced acute renal failureDelayed Methotrexate Clearance in a Patient With Sickle Cell Anemia and OsteosarcomaEffects of hemoperfusion plus high-flux hemodialysis in a patient with methotrexate toxicitySuccessful Rescue in a Patient with High Dose Methotrexate-Induced Nephrotoxicity and Acute Renal FailureCase 14-1996Anticancer drugs and immunomodulatorsCarboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicityClinical use of thymidine as a rescue agent from methotrexate toxicityMHemoperfusionPharmacological Considerations for Renal Failure and DialysisClinical HaemoperfusionRemoval of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusionToxic NephropathiesNephrotoxicity Induced by Cancer Chemotherapy With Special Emphasis on Cisplatin ToxicityCHARCOAL HAEMOPERFUSION AND METHOTREXATE TOXICITYAntiinflammatory and Immunosuppressive Drugs in the Treatment of Rheumatoid ArthritisKinetics of the Redistribution Phenomenon after Extracorporeal EliminationDrug Prescribing in Renal Failure: Dosing Guidelines for AdultsDrugs and DialysisThe clinical pharmacology of methotrexatePharmacological Aspects of Renal Failure and DialysisDrug Therapy in Renal Failure: Dosing Guidelines for Adults Part II: Sedatives, Hypnotics, and Tranquilizers; Cardiovascular, Antihypertensive, and Diuretic Agents; Miscellaneous AgentsWILLIAM M. BENNETT, M.D., RICHARD S. MUTHER, M.D., RICHARD A. PARKER, M.D., PETER FEIG, M.D., GAIL MORRISON, M.D., THOMAS A. GOLPER, M.D., IRWIN SINGER, M.D.Will Hemoperfusion Be Useful for Cancer Chemotherapeutic Drug Removal?Extracorporeal Blood Purification Techniques: Plasmapheresis and Hemoperfusion 1 October 1977Volume 87, Issue 4Page: 495-496KeywordsCreatinineExcretionHead and neck tumorsMethotrexateSarcomaToxicity ePublished: 1 December 2008 Issue Published: 1 October 1977 PDF downloadLoading ...